C4 Therapeutics (CCCC) Share-based Compensation (2019 - 2026)

C4 Therapeutics' Share-based Compensation history runs 8 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 51.5% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $16.3 million (down 43.83% YoY), while the FY2025 annual figure was $19.1 million, down 35.61% from the prior year.
• Share-based Compensation was $2.7 million for Q1 2026 at C4 Therapeutics, down from $4.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $8.9 million in Q1 2022 to a low of $2.7 million in Q1 2026.
• Historically, Share-based Compensation has averaged $6.4 million across 5 years, with a median of $6.4 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Share-based Compensation jumped 132.46% in 2022, then sank 51.5% in 2026.
• A 5-year view of Share-based Compensation shows it stood at $6.9 million in 2022, then slipped by 8.09% to $6.4 million in 2023, then rose by 29.5% to $8.2 million in 2024, then tumbled by 51.34% to $4.0 million in 2025, then sank by 33.34% to $2.7 million in 2026.
• The last three Share-based Compensation figures came in at $2.7 million (Q1 2026), $4.0 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.